<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Oral isotretinoin therapy for acne vulgaris</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Oral isotretinoin therapy for acne vulgaris</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Oral isotretinoin therapy for acne vulgaris</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Cindy Owen, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Robert P Dellavalle, MD, PhD, MSPH</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Moise L Levy, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jeffrey Callen, MD, FACP, FAAD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Abena O Ofori, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Mar 24, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Oral <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a> (13-cis retinoic acid) is a retinoid most often used for the treatment of acne vulgaris, particularly severe or recalcitrant disease. Isotretinoin is teratogenic and associated with a number of other adverse effects that can limit its use. Thus, it must be used with caution and should only be prescribed by clinicians who are completely familiar with the medication.</p><p>The clinical use of oral <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a> for acne vulgaris will be reviewed here. Discussions of the clinical manifestations, diagnosis, and approach to treatment for acne vulgaris as well as detailed drug information on isotretinoin are provided separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/39.html" rel="external">"Pathogenesis, clinical manifestations, and diagnosis of acne vulgaris"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/42.html" rel="external">"Acne vulgaris: Overview of management"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/129467.html" rel="external">"Acne vulgaris: Management of moderate to severe acne in adolescents and adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/13615.html" rel="external">"Postadolescent acne in women"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/131570.html" rel="external">"Acne in infants, young children, and preadolescents"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/90260.html" rel="external">"Management of acne scars"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="drug drug_general" href="/z/d/drug information/8582.html" rel="external">"Isotretinoin: Drug information"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="drug drug_pediatric" href="/z/d/drug information/13395.html" rel="external">"Isotretinoin: Pediatric drug information"</a>.)</p><p></p><p class="headingAnchor" id="H2"><span class="h1">MECHANISM OF ACTION</span><span class="headingEndMark"> — </span>Oral <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a> counteracts the pathogenic factors that contribute to the development of acne vulgaris [<a href="#rid1">1,2</a>]. Therapy leads to shrinkage of sebaceous glands and a marked attenuation of sebum secretion. The decrease in sebum results in the inhibition of the sebum-dependent bacterium <em>Cutibacterium</em> (formerly <em>Propionibacterium</em>)<em> acnes</em>, which is a key promoter of inflammation in acne vulgaris. Direct anti-inflammatory effects of oral isotretinoin may occur through normalization of the toll-like receptor 2-mediated innate immune response to <em>C. acnes </em>[<a href="#rid3">3</a>]. Oral isotretinoin also inhibits comedogenesis by fostering keratinocyte differentiation and by normalizing desquamation. (See  <a class="medical medical_review" href="/z/d/html/39.html" rel="external">"Pathogenesis, clinical manifestations, and diagnosis of acne vulgaris", section on 'Pathogenesis'</a>.)</p><p class="headingAnchor" id="H3066357438"><span class="h1">ADVERSE EFFECTS</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">Isotretinoin</a> is a teratogenic drug that is associated with a broad range of mucocutaneous and extracutaneous adverse effects. Side effects of isotretinoin are usually manageable, permitting continuation of therapy. In a 2018 systematic review of 11 randomized trials, severe adverse events requiring withdrawal from trials occurred in only 12 of 372 patients taking isotretinoin (3 percent). The severe adverse events included Stevens-Johnson syndrome, cheilitis, xerosis, acne flare, photophobia, elevated liver enzymes, decreased appetite, headaches, and depressed mood [<a href="#rid4">4</a>].</p><p>The management of common side effects is reviewed below. (See <a class="local">'Management of complications'</a> below.)</p><p class="headingAnchor" id="H1232358957"><span class="h2">Mucocutaneous</span><span class="headingEndMark"> — </span>The common mucocutaneous side effects of <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a>, including cheilitis, dry skin and mucous membranes, epistaxis, desquamation, photosensitivity, and pruritus, are predictable and dose dependent. In the systematic review, dermatologic side effects represented nearly 65 percent of all reported side effects, with cheilitis and xerosis as the most frequent [<a href="#rid4">4</a>].</p><p><a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">Isotretinoin</a> is also associated with risk for ocular abnormalities (eg, dryness, irritation, conjunctivitis) related to dysfunction of meibomian glands within the conjunctiva [<a href="#rid4">4-6</a>]. Cutaneous staphylococcal infections may also occur [<a href="#rid7">7</a>]. Paronychia, pyogenic granulomas, temporary diffuse alopecia, and nail brittleness occasionally appear [<a href="#rid8">8</a>].</p><p>Transient worsening of acne may occur in the beginning of <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a> therapy. Rarely, isotretinoin induces acne fulminans, a severe manifestation [<a href="#rid9">9,10</a>]. (See <a class="local">'Severe acne'</a> below.)</p><p class="headingAnchor" id="H2191710542"><span class="h2">Teratogenicity</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">Isotretinoin</a> causes severe, life-threatening, congenital malformations and spontaneous abortions [<a href="#rid11">11</a>]. Embryopathy associated with exposure in the first trimester of pregnancy includes craniofacial, cardiac, thymic, and central nervous system malformations [<a href="#rid12">12</a>]. Fetal abnormalities have not been attributed to the use of isotretinoin in men [<a href="#rid2">2</a>]. (See  <a class="medical medical_review" href="/z/d/html/110900.html" rel="external">"Congenital anomalies: Causes", section on 'Drug exposure'</a>.)</p><p>Among pregnant women exposed to <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a>, the risk of spontaneous abortion is approximately 20 percent; among pregnancies that progress, approximately 20 to 30 percent of neonates have evidence of embryopathy [<a href="#rid13">13</a>]. Although data are limited, children who appear physically normal may still have a higher rate of intellectual disability and impaired neuropsychologic function [<a href="#rid13">13</a>].</p><p class="headingAnchor" id="H1918284488"><span class="h2">Psychiatric effects</span><span class="headingEndMark"> — </span>The relationship between <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a> therapy and depression and suicide is uncertain. Reviews, including a systematic review and meta-analysis, have concluded that data on suicidal behavior and depression during treatment with isotretinoin are inadequate to establish a causal relationship [<a href="#rid14">14-18</a>]. Given the uncertainty, patients should be advised of a possible link and should be followed closely for the development of depression or suicidal ideation. (See  <a class="medical medical_review" href="/z/d/html/1708.html" rel="external">"Suicidal ideation and behavior in adults"</a> and  <a class="medical medical_review" href="/z/d/html/1230.html" rel="external">"Suicidal ideation and behavior in children and adolescents: Evaluation and management"</a>.)</p><p>Some authors have proposed that psychologic distress over severe acne, rather than <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a>, could be a contributing factor to occurrences of suicide or depression in patients treated with the drug [<a href="#rid19">19-21</a>]. In a population-based cohort study, risk for major depressive disorder was higher among patients with acne than in the general population without acne [<a href="#rid20">20</a>]. The risk was unchanged after excluding patients who received isotretinoin. (See  <a class="medical medical_review" href="/z/d/html/1224.html" rel="external">"Pediatric unipolar depression: Epidemiology, clinical features, assessment, and diagnosis"</a>.) </p><p>A large, global, retrospective cohort study provides additional support for relative safety of <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a> therapy in regard to some psychiatric outcomes [<a href="#rid22">22</a>]. The study used electronic health record data to compare psychiatric outcomes from patients with acne treated with isotretinoin (n = 75,708) with outcomes from patients with acne treated with oral antibiotics who also had no documentation of isotretinoin therapy (n = 75,708). Although there was an increase in risk for suicidal ideation among patients treated with isotretinoin (hazard ratio [HR] 1.41, 95% CI 1.32-1.50), there was no increase in suicidal attempts (HR 0.97, 95% CI 0.85-1.11) or major depressive disorder (HR 0.97, 95% CI 0.92-1.03). Risk for depression, post-traumatic stress disorder, anxiety, bipolar disorder, schizophrenia, and adjustment disorder were lower in patients treated with isotretinoin.</p><p class="headingAnchor" id="H1044262945"><span class="h2">Inflammatory bowel disease</span><span class="headingEndMark"> — </span>Although observational studies have found conflicting results on the relationship between <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a> therapy and inflammatory bowel disease (IBD), analysis of the available data suggests that isotretinoin therapy is not a risk factor for IBD. A 2012 meta-analysis of three case-control studies and two additional unpublished studies did not find a statistically significant relationship between isotretinoin therapy and IBD (relative risk for IBD 0.94, 95% CI 0.65-1.36) [<a href="#rid23">23</a>]. Several subsequent, large, cohort studies also suggest that isotretinoin therapy for acne does not increase risk for IBD:</p><p class="bulletIndent1"><span class="glyph">●</span>A 12-year cohort study of 46,922 patients treated with <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a>, 184,824 patients treated with topical acne medication, and 1,526,946 untreated controls (all between the ages of 12 and 29) did not find a significant association between isotretinoin use and IBD on primary analysis (rate ratio 1.14, 95% CI 0.92-1.41) [<a href="#rid24">24</a>]. Although an association between isotretinoin and IBD was detected in a subgroup of patients aged 12 to 19 years (rate ratio 1.39, 95% CI 1.03-1.87), a similar association was detected between the use of topical acne medications and ulcerative colitis (rate ratio 1.19, 95% CI 1.00-1.42), suggesting an association between acne and IBD independent of treatment.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A retrospective cohort study that used electronic health record data to compare risk for IBD and irritable bowel syndrome in patients with acne treated with <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a> (n = 77,005) with risk for these diseases in patients with acne treated with oral antibiotics but not isotretinoin (n = 77,005) found similar lifetime risk for both Crohn disease (HR 1.05, 95% CI 0.89-1.24) and ulcerative colitis (HR 1.13, 95% CI 0.95-1.34) between the two groups [<a href="#rid25">25</a>]. An increase in risk for ulcerative colitis in the first six months after starting isotretinoin (HR 1.93, 95% CI 1.29-2.88) resolved after this period and was associated with a low absolute risk difference (5 additional cases per 100,000 patients starting isotretinoin, 95% CI 2.5-7.7). Risk for irritable bowel syndrome was lower for patients in the isotretinoin therapy group than for patients in the oral antibiotics group.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A retrospective cohort study performed with electronic health record data did not find an association between oral <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a> therapy and risk for incident IBD within one year [<a href="#rid26">26</a>]. The study compared the risk of incident IBD in four groups: patients without acne (n = 353,381), patients with acne that was not treated with systemic medication (n = 351,570), patients with acne treated with oral <a class="drug drug_general" data-topicid="9986" href="/z/d/drug information/9986.html" rel="external">tetracycline</a> antibiotics (n = 144,986), and patients with acne treated with isotretinoin (n = 11,199). The risk of incident IBD within one year in patients treated with isotretinoin did not differ from the risk in patients who did not receive systemic therapy for their acne (odds ratio [OR] 1.29, 95% CI 0.64-2.59) or from patients who were treated with oral antibiotics (OR 1.13, 95% CI 0.57-2.21). There was an association between acne and risk for incident IBD (OR 1.42, 95% CI 1.23-1.65), but the absolute risk remained small (0.04 percent, 95% CI 0.02-0.05 percent).</p><p></p><p>More studies are necessary to confirm whether <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a> therapy is a risk factor for IBD. Until additional information is available, during discussions of the potential adverse effects of isotretinoin with patients, it is reasonable to mention that although an increased risk for IBD has been reported, a relationship between these disorders has not been proven.</p><p class="headingAnchor" id="H3080383249"><span class="h2">Hyperlipidemia</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">Isotretinoin</a> has been associated with a number of other side effects [<a href="#rid4">4</a>]. Hypertriglyceridemia is common, occurring in up to 45 percent of patients taking isotretinoin, and total cholesterol and low-density lipoprotein elevations occur in approximately 30 percent [<a href="#rid27">27</a>]. The development of hyperlipidemia during isotretinoin therapy may be associated with increased risk for future development of hyperlipidemia and metabolic syndrome [<a href="#rid28">28</a>]. (See <a class="local">'Laboratory abnormalities'</a> below.)</p><p class="headingAnchor" id="H1807049629"><span class="h2">Other side effects</span><span class="headingEndMark"> — </span>Other less common side effects include myalgias (particularly in patients who engage in vigorous physical activity), visual changes (decreased night vision, corneal opacities), hepatotoxicity, bone marrow suppression, idiopathic intracranial hypertension (pseudotumor cerebri), and bone changes (hyperostosis and, rarely, premature epiphyseal closure) [<a href="#rid29">29-33</a>]. (See  <a class="medical medical_review" href="/z/d/html/5254.html" rel="external">"Idiopathic intracranial hypertension (pseudotumor cerebri): Epidemiology and pathogenesis", section on 'Medications'</a>.)</p><p>For additional information on <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a> side effects, refer to the Lexicomp drug information monograph included within UpToDate. (See  <a class="drug drug_general" href="/z/d/drug information/8582.html" rel="external">"Isotretinoin: Drug information"</a>.)</p><p class="headingAnchor" id="H275150214"><span class="h1">CONTRAINDICATIONS AND PRECAUTIONS</span></p><p class="headingAnchor" id="H2800945565"><span class="h2">Contraindications</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">Isotretinoin</a> should <strong>not</strong> be given to pregnant individuals or individuals who may become pregnant during or within one month after therapy. Effective measures to prevent pregnancy are indicated for all individuals who could become pregnant. Also, individuals with a history of hypersensitivity to isotretinoin or any of its components should not receive isotretinoin. Isotretinoin capsules contain soybean oil and should be used with caution in patients with severe soy allergy.</p><p class="headingAnchor" id="H159593915"><span class="h2">Drug interactions</span><span class="headingEndMark"> — </span>Simultaneous treatment with medications that share the side effect of idiopathic intracranial hypertension with <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a>, such as tetracyclines, should be avoided. In addition, <a class="drug drug_general" data-topicid="10047" href="/z/d/drug information/10047.html" rel="external">vitamin A</a> supplementation may increase the adverse effects of isotretinoin and should be avoided. A list of additional drug interactions is provided separately. (See  <a class="drug drug_general" href="/z/d/drug information/8582.html" rel="external">"Isotretinoin: Drug information"</a>.)</p><p>Specific interactions of <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a> with other medications may be determined using the <a class="external" href="/drug-interactions">drug interactions program</a> included in UpToDate. This program can also be accessed from the UpToDate online search page or through the individual drug information topics (also referred to as monographs) in the section on Drug interactions.</p><p class="headingAnchor" id="H1282151592"><span class="h2">Children</span><span class="headingEndMark"> — </span>The effectiveness and safety of <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a> has not been established in children under 12 years of age.</p><p class="headingAnchor" id="H853922788"><span class="h2">Cutaneous procedures</span><span class="headingEndMark"> — </span>Delaying cutaneous procedures until at least six months after the completion of oral <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a> therapy has been historically practiced due to concern for increased risk for abnormal scarring and delayed wound healing. However, the available data suggest that this may not be necessary for some procedures.</p><p>Based upon a systematic review of the literature, a multispecialty panel of experts found insufficient evidence to recommend delaying manual dermabrasion, superficial chemical peels, cutaneous surgery, laser hair removal, and fractional ablative and nonablative laser procedures for patients with current or recent <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a> use [<a href="#rid34">34</a>]. The panel recommended avoidance of mechanical dermabrasion and fully ablative laser procedures in patients with recent isotretinoin use based upon limited evidence suggesting increased risk for scarring. A task force from the American Society for Dermatologic Surgery (ASDS) reached similar conclusions, with the exception of specifying that while focal or superficial manual dermabrasion does not appear to be associated with increased risk for scarring or delayed wound healing, full-face manual dermabrasion is not recommended within six months after isotretinoin therapy [<a href="#rid35">35</a>]. </p><p>Although prospective, controlled trials are necessary to confirm the level of risk associated with cutaneous procedures in this population, the findings of the systematic review and ASDS task force aid in counseling patients who may benefit from earlier performance of procedures.</p><p class="headingAnchor" id="H1081177031"><span class="h2">Alcohol use</span><span class="headingEndMark"> — </span>Although alcohol consumption is not contraindicated during <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a> therapy, we generally counsel patients to avoid excessive alcohol consumption. Similar to isotretinoin, alcohol consumption may contribute to hypertriglyceridemia and hepatic transaminase elevations. Moreover, excessive alcohol consumption may contribute to impaired judgment and substandard use of pregnancy prevention methods and has negative effects on overall health. (See  <a class="medical medical_review" href="/z/d/html/2781.html" rel="external">"Overview of the risks and benefits of alcohol consumption"</a>.)</p><p class="headingAnchor" id="H2766716797"><span class="h1">INITIATION OF THERAPY</span><span class="headingEndMark"> — </span>The initiation of <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a> therapy involves careful patient counseling and a pretreatment clinical and laboratory assessment. The goal is to support successful treatment and minimize risk for serious adverse effects. (See <a class="local">'Patient counseling'</a> below and <a class="local">'Baseline clinical and laboratory evaluation'</a> below and <a class="local">'Dosing and administration'</a> below and <a class="local">'Use of other acne medications'</a> below.)</p><p class="headingAnchor" id="H332344540"><span class="h2">Patient counseling</span><span class="headingEndMark"> — </span>In addition to a discussion of the risks and benefits of treatment, patients who will begin <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a> therapy should be thoroughly informed of the monitoring and pregnancy prevention measures that are required for isotretinoin therapy. Some countries have implemented mandatory risk management programs designed to prevent fetal exposure to isotretinoin, though positive effects of such programs on reducing fetal exposure are unproven [<a href="#rid36">36</a>]. </p><p>In the United States, prescribing and receipt of <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a> requires participation in the iPLEDGE program. The iPLEDGE program provides detailed guidelines for pregnancy prevention counseling, pregnancy screening, and contraceptive use during treatment. (See <a class="local">'iPLEDGE program'</a> below.)</p><p>In general, prescribing clinicians should be able to discuss contraceptive options and appropriate use with patients of childbearing potential. Alternatively, these patients should be referred to a provider who can provide this service. All patients who are at risk for pregnancy during treatment should begin highly effective contraceptive measures one month prior to, during, and for one month after completion of <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a> therapy. In addition, patients should avoid sharing isotretinoin pills with others and should avoid blood donation during therapy and for one month after completion of therapy.</p><p>A discussion of the ocular side effects of <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a> may be particularly important for patients in occupations with strict guidelines for vision, such as airline pilots. In the United States, the Federal Aviation Administration has <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.faa.gov%2Fabout%2Foffice_org%2Fheadquarters_offices%2Favs%2Foffices%2Faam%2Fame%2Fguide%2Fpharm%2Facne%2F&amp;token=34eHBTBtq%2BU7RsfQ1hlTei%2BysuXc14Z62VutMxlhFSRdZiJN4VxfXcaQC%2F5KUhX5pAJXutteQKkW%2F5JWEIahaTHZASh%2FJQTXHBIv99qB4OKvALUkLBSw0hah5bEtTSir&amp;TOPIC_ID=38" target="_blank">policies</a> regarding isotretinoin therapy.</p><p class="headingAnchor" id="H4166722259"><span class="h3">iPLEDGE program</span><span class="headingEndMark"> — </span>In 2006, the US Food and Drug Administration (FDA) established a computer-based Risk Evaluation and Mitigation Strategy (REMS) risk management program with the goal of eliminating fetal exposure to <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a> (iPLEDGE). Prescribers, pharmacies dispensing isotretinoin, wholesalers distributing isotretinoin, and all patients receiving isotretinoin are required to comply with the registry requirements.</p><p>Access to the iPLEDGE program is available <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fipledgeprogram.com%2F%23Main&amp;token=11npaxc5%2BtwYQNEbNxIvNQfcJaSKzBwVKphwr4ut8b7qoeyGYSAd9yUzO5kFibik&amp;TOPIC_ID=38" target="_blank">online</a>. The iPLEDGE program requires the following [<a href="#rid37">37</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>All patients who can get pregnant must select and commit to the use of two forms of birth control for at least one month prior to starting <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a> therapy, during therapy, and for one month after therapy. The forms of contraception that meet these requirements are specified by the iPLEDGE program.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>All patients who can get pregnant must have two negative urine or blood pregnancy tests (with a sensitivity of at least 25 milli-international units/mL) before receiving the initial prescription. The second pregnancy test must be conducted in a Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory. For each month of therapy and one month after completing therapy, patients must return to their clinicians for evaluation, counseling, education, and a pregnancy test conducted by a CLIA-certified laboratory.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients who can get pregnant, prescribing clinicians must, on a monthly basis, document in the iPLEDGE system the results of the pregnancy test as well as report the two forms of birth control being used by the patient. The clinician must also confirm that the patient has received counseling and education. For all other patients, prescribers must document that the patient was counseled on the iPLEDGE program requirements, which include knowledge of the fetal injury that may result from the use of <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a> by individuals of childbearing potential.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>As part of this system, clinicians must certify expertise in the diagnosis and treatment of acne and knowledge of the risk and severity of fetal injury with <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a>.</p><p></p><p class="headingAnchor" id="H1235054766"><span class="h2">Baseline clinical and laboratory evaluation</span><span class="headingEndMark"> — </span>The pretreatment clinical and laboratory evaluation serves to identify patients who are not candidates for <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a> therapy (eg, pregnant individuals) and patients who may require closer monitoring during therapy. Examples of patients for whom additional counseling or monitoring may be helpful include patients with [<a href="#rid2">2</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Prior contraceptive failure</p><p class="bulletIndent1"><span class="glyph">●</span>History of uncontrolled depression or suicidal ideation</p><p class="bulletIndent1"><span class="glyph">●</span>Hyperlipidemia or family history of early-onset hyperlipidemia</p><p class="bulletIndent1"><span class="glyph">●</span>Personal or family history of inflammatory bowel disease</p><p class="bulletIndent1"><span class="glyph">●</span>Eye or vision problems (particularly dry eyes and contact lens use)</p><p class="bulletIndent1"><span class="glyph">●</span>Heavy alcohol use</p><p class="bulletIndent1"><span class="glyph">●</span>Extreme physical activity</p><p></p><p>Current medications should be reviewed to identify potential drug interactions. In particular, treatment with other drugs that may cause pseudotumor cerebri, such as tetracyclines, should be avoided. (See <a class="local">'Drug interactions'</a> above.)</p><p>Baseline laboratory testing is indicated to identify pregnant patients and patients with liver or lipid abnormalities. In the past, obtaining full liver function, lipid, and complete blood count panels in addition to a urine or serum pregnancy test for individuals who could become pregnant was common. However, the need for this extent of testing in healthy patients has been questioned [<a href="#rid38">38</a>]. (See <a class="local">'Laboratory monitoring'</a> below.)</p><p>Our typical pretreatment tests include:</p><p class="bulletIndent1"><span class="glyph">●</span>Alanine aminotransferase (ALT) and triglyceride levels within one month prior to the start of therapy</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Urine or serum pregnancy test in individuals of childbearing potential (note that two tests are required prior to the start of therapy for the iPLEDGE program) (see <a class="local">'iPLEDGE program'</a> above)</p><p></p><p class="headingAnchor" id="H1754390815"><span class="h2">Dosing and administration</span><span class="headingEndMark"> — </span>Absorption of <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a> is improved when taken with food (especially high-fat meals); thus, administration during meals is recommended. A formulation of isotretinoin that uses lipid encapsulation technology to enclose isotretinoin demonstrates increased bioavailability in the fasting state [<a href="#rid39">39</a>]. This formulation is dosed twice daily and can be given without regard to meals.</p><p class="headingAnchor" id="H3799325582"><span class="h3">Severe acne</span><span class="headingEndMark"> — </span>Severe acne is considered acne with many inflammatory nodules or other severe features (eg, extensive involvement of one or more body regions with comedonal or papulopustular acne)  (<a class="graphic graphic_picture graphicRef55681 graphicRef59878 graphicRef98493 graphicRef117250 graphicRef115821 graphicRef57925" href="/z/d/graphic/55681.html" rel="external">picture 1A-F</a>). The treatment goal for these patients is a cumulative dose of 120 to 150 mg/kg of <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a> to decrease the risk of acne recurrence [<a href="#rid33">33</a>]. Most patients achieve this goal within 20 to 24 weeks.</p><p>Treatment is usually initiated at a dose of 0.5 mg/kg per day for the first month of therapy to minimize risk for isotretinoin-induced acne flares and is subsequently increased to 1 mg/kg per day. The total daily dose of <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a> is typically divided in two doses taken with food; alternatively, isotretinoin can be taken once daily to increase adherence to therapy.</p><p>Isotretinoin-induced acne flaring or acne fulminans may occur at the start of <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a> therapy in patients with severe inflammatory acne (eg, acne conglobata, acne fulminans) or deep comedonal acne. Starting doses lower than 0.5 mg/kg per day are suggested for this population. In addition, systemic glucocorticoids may be given prior to the start of isotretinoin or concurrently for the first two to four weeks. (See  <a class="medical medical_review" href="/z/d/html/129467.html" rel="external">"Acne vulgaris: Management of moderate to severe acne in adolescents and adults", section on 'Acne conglobata'</a> and  <a class="medical medical_review" href="/z/d/html/129467.html" rel="external">"Acne vulgaris: Management of moderate to severe acne in adolescents and adults", section on 'Acne fulminans'</a>.)</p><p>There is some evidence that high cumulative doses (eg, ≥220 mg/kg) of <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a> may reduce the risk of relapse in patients with severe acne vulgaris [<a href="#rid40">40,41</a>]. Additional studies are needed to confirm this finding as well as the safety of high-dose isotretinoin therapy.</p><p class="headingAnchor" id="H1704602724"><span class="h3">Moderate acne</span><span class="headingEndMark"> — </span>Moderate acne appropriate for <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a> therapy may be considered less extensive acne that is treatment resistant, relapses rapidly after cessation of oral antibiotic therapy, scars, or induces significant psychosocial distress  (<a class="graphic graphic_picture graphicRef70809" href="/z/d/graphic/70809.html" rel="external">picture 2</a>) [<a href="#rid33">33</a>]. Patients with moderate acne are usually treated with a regimen identical to that used for severe acne, achieving a cumulative dose of 120 to 150 mg/kg over the course of 20 to 24 weeks.</p><p>However, a lower-dose regimen (0.3 to 0.5 mg/kg per day for the duration of therapy) may be an alternative [<a href="#rid33">33,42</a>]. The advantage of this lower dose is reduced risk for drug side effects [<a href="#rid33">33</a>].</p><p>A 24-week, single-blind, randomized trial in which 60 patients with moderate acne were treated with one of three regimens of <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a>, 0.5 to 0.7 mg/kg per day (higher-dose regimen), 0.25 to 0.4 mg/kg per day (lower-dose regimen), or 0.5 to 0.7 mg/kg daily for one week every four weeks (intermittent regimen), supports efficacy of lower-dose therapy [<a href="#rid43">43</a>]. All three treatment courses resulted in clinically significant improvement and marked reductions in mean acne lesion counts. The lower-dose and higher-dose regimens were similarly effective and had equivalent rates of relapse after one year; however, more adverse effects were reported in the higher-dose group during treatment. A lesser degree of improvement and a lower duration of effect were detected in the patients who received intermittent therapy. </p><p class="headingAnchor" id="H1077560867"><span class="h2">Use of other acne medications</span><span class="headingEndMark"> — </span>Other acne medications are typically discontinued at the start of <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a> therapy. Isotretinoin causes temporary xerosis, cutaneous atrophy, and skin fragility, and topical acne medications may be poorly tolerated [<a href="#rid2">2</a>]. Isotretinoin should not be given with tetracyclines due to the risk of idiopathic intracranial hypertension (pseudotumor cerebri) associated with both of these drugs.</p><p class="headingAnchor" id="H3074377969"><span class="h1">DURING THERAPY</span><span class="headingEndMark"> — </span>Follow-up visits are typically held on a monthly basis to assess response and side effects, address patient questions, and fulfill the counseling and monitoring requirements of the iPLEDGE program.</p><p class="headingAnchor" id="H1578941919"><span class="h2">Clinical assessment</span><span class="headingEndMark"> — </span>Patient assessment should include a patient history and skin examination to assess for response and adverse effects. We typically ask the patient about the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Perceived worsening/improvement of acne</p><p class="bulletIndent1"><span class="glyph">●</span>Dryness of skin or mucous membranes</p><p class="bulletIndent1"><span class="glyph">●</span>Nosebleeds</p><p class="bulletIndent1"><span class="glyph">●</span>Vision changes</p><p class="bulletIndent1"><span class="glyph">●</span>Headaches</p><p class="bulletIndent1"><span class="glyph">●</span>Abdominal pain</p><p class="bulletIndent1"><span class="glyph">●</span>Joint, muscle, or bone pain</p><p class="bulletIndent1"><span class="glyph">●</span>Bowel symptoms</p><p class="bulletIndent1"><span class="glyph">●</span>Mood changes, symptoms of depression, or suicidality</p><p></p><p>We examine involved skin as well as any other areas of concern for the patient. In our experience, signs of improvement in acne often become evident after the first one to two months of therapy, with progressive improvement over subsequent months.</p><p class="headingAnchor" id="H3400381119"><span class="h2">Laboratory monitoring</span><span class="headingEndMark"> — </span>Laboratory monitoring <strong>during</strong> <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a> therapy generally consists of assessments for pregnancy, liver dysfunction, and dyslipidemia. Baseline and post-treatment testing are reviewed separately. (See <a class="local">'Baseline clinical and laboratory evaluation'</a> above and <a class="local">'Follow-up'</a> below.)</p><p class="headingAnchor" id="H1659966227"><span class="h3">Test selection and frequency</span><span class="headingEndMark"> — </span>Historically, monthly checking of full liver function and lipid panels during <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a> treatment was a routine and well-accepted practice. <strong>However</strong>, in otherwise healthy, asymptomatic, young individuals without a personal or family history of diabetes or dyslipidemia, there are data that suggest it may be safe to perform less extensive and less frequent testing. (See <a class="local">'Evidence'</a> below.)</p><p>Monitoring of complete blood count panels is <strong>not</strong> necessary in the absence of a known abnormality or risk factor for leukopenia. There are differing opinions on the need for monitoring creatine kinase levels. In general, obtaining a creatine kinase level is not indicated in the absence of severe muscular pain [<a href="#rid2">2</a>].</p><p>Our approach to laboratory monitoring <strong>during</strong> <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a> therapy is as follows [<a href="#rid44">44</a>] (see <a class="local">'Baseline clinical and laboratory evaluation'</a> above):</p><p class="bulletIndent1"><span class="glyph">●</span>Monthly pregnancy tests in individuals who can become pregnant. (See <a class="local">'iPLEDGE program'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If baseline alanine aminotransferase (ALT) and triglyceride levels were normal, these tests should be repeated after the peak <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a> dose is reached (we typically obtain these tests one month after starting the peak dose, which is usually after completion of a total of two months of isotretinoin therapy). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If the results of testing after reaching the peak dose are normal and the dose of <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a> is not increased, then further monitoring is not required. If the results of testing are abnormal or if the patient has a known lipid abnormality, then periodic monitoring should be continued. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Development of new symptoms (eg, abdominal pain), the initiation of new medications or supplements, or an increase in the dose of <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a> may warrant retesting.</p><p></p><p class="headingAnchor" id="H1481967826"><span class="h3">Evidence</span><span class="headingEndMark"> — </span>Examples of studies suggesting that a more limited approach to laboratory testing in healthy patients is reasonable include:</p><p class="bulletIndent1"><span class="glyph">●</span>The findings of a systematic review and meta-analysis of studies reporting laboratory values during <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a> therapy for acne support less frequent testing; although isotretinoin was associated with statistically significant changes in the mean values of some laboratory tests (white blood cell count, hepatic panel, lipid panel), the changes did not meet criteria for high risk, and the proportion of patients with laboratory abnormalities was low [<a href="#rid45">45</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a retrospective study of 903 patients treated with <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a> for acne vulgaris, no clinically significant hematologic abnormalities were detected during treatment [<a href="#rid46">46</a>]. Although patients experiencing elevation of triglyceride levels (n = 197), ALT (n = 113), and aspartate aminotransferase (AST; n = 102) were common, all but seven cases of triglyceride, ALT, or AST elevation were successfully managed with observation or lowering of the isotretinoin dose, and all elevations resolved after completion of isotretinoin.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A Delphi consensus study that involved the administration of four rounds of anonymous surveys on <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a> laboratory monitoring to a group of 22 international acne experts provides additional support [<a href="#rid38">38</a>]. Tests evaluated included the components of liver function, basal metabolic, lipid, and complete blood count panels, as well as creatine kinase and C-reactive protein levels. Consensus was defined by agreement among ≥70 percent of participants.</p><p></p><p class="bulletIndent1">Interventions that met consensus criteria included obtaining ALT and triglyceride levels within one month prior to initiation of <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a> and after reaching peak dose. There was consensus that the following were<strong> not</strong> necessary: obtaining ALT or triglyceride levels monthly or after completion of isotretinoin therapy; obtaining complete blood count or basal metabolic panels at any point during treatment; and checking gamma-glutamyl transferase, bilirubin, albumin, total protein, low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), or C-reactive protein levels at any point during treatment. There was no consensus on practices for checking AST, alkaline phosphatase, creatine kinase, and total cholesterol levels.</p><p></p><p class="headingAnchor" id="H3102589135"><span class="h2">Management of complications</span><span class="headingEndMark"> — </span>Most of the adverse effects associated with <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a> can be managed without discontinuing the drug.</p><p class="headingAnchor" id="H3487803049"><span class="h3">Exacerbation of acne</span><span class="headingEndMark"> — </span>Transient worsening of acne may occur during the first month of treatment, particularly in patients with severe disease (see <a class="local">'Severe acne'</a> above). Significant flares may require adjustments to therapeutic approach. For mild flares, no adjustment in treatment is needed. </p><p>The approach to isotretinoin-induced acne fulminans is reviewed separately  (<a class="graphic graphic_picture graphicRef64372" href="/z/d/graphic/64372.html" rel="external">picture 3</a> and <a class="graphic graphic_algorithm graphicRef113850" href="/z/d/graphic/113850.html" rel="external">algorithm 1</a>). (See  <a class="medical medical_review" href="/z/d/html/129467.html" rel="external">"Acne vulgaris: Management of moderate to severe acne in adolescents and adults", section on 'Acne fulminans'</a>.)</p><p class="headingAnchor" id="H875439994"><span class="h3">Mucocutaneous</span><span class="headingEndMark"> — </span>Dry skin and mucous membranes are common during treatment. In particular, cheilitis can be significant and often requires the liberal use of topical emollients, such as petroleum jelly or other lip moisturizers. </p><p>To minimize dry skin, patients are advised to wash with a gentle, nondetergent cleanser followed by the application of emollients. A noncomedogenic emollient is recommended for acne-prone skin areas. (See  <a class="medical medical_review" href="/z/d/html/1730.html" rel="external">"Treatment of atopic dermatitis (eczema)", section on 'Emollients and moisturizers'</a>.)</p><p>For patients with nasal crusting or dryness or with epistaxis, <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a> nasal spray and application of petroleum jelly to the nostrils can be helpful. <a class="drug drug_general" data-topicid="8660" href="/z/d/drug information/8660.html" rel="external">Artificial tears</a> may help to reduce symptoms of eye dryness. Patients who wear contact lenses may not be able to tolerate them during treatment and may need to discontinue their use.  </p><p>Sun-protective measures are indicated to minimize the effects of isotretinoin-induced photosensitivity. Patients should use a facial moisturizer with a sun protection factor (SPF) of at least 30 daily, and sun-protective clothing should be worn during sun exposure. Sunscreen should be applied to exposed skin areas prior to sun exposure and reapplied every two to three hours. (See  <a class="medical medical_review" href="/z/d/html/13751.html" rel="external">"Selection of sunscreen and sun-protective measures"</a>.)</p><p class="headingAnchor" id="H829563718"><span class="h3">Myalgias</span><span class="headingEndMark"> — </span>Although checking of creatine kinase (CK) levels is not indicated in the absence of severe muscle pain, CK levels are elevated in approximately 15 to 50 percent of patients with isotretinoin-induced myalgias [<a href="#rid2">2</a>]. Mild to moderate pain usually can be managed with anti-inflammatory drugs. <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">Isotretinoin</a> should be discontinued if pain becomes severe or cannot be improved with anti-inflammatory drugs [<a href="#rid2">2</a>]. </p><p class="headingAnchor" id="H3037992878"><span class="h3">Laboratory abnormalities</span><span class="headingEndMark"> — </span>Hypertriglyceridemia, hepatic transaminase elevations, and CK elevations are common laboratory abnormalities during <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a> treatment:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hypertriglyceridemia</strong> – Minor or moderate elevations in triglyceride levels (300 to 500 mg/dL) do not necessitate alteration of the <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a> dose and can be managed with lifestyle modification [<a href="#rid47">47</a>]. (See  <a class="medical medical_review" href="/z/d/html/4570.html" rel="external">"Hypertriglyceridemia in adults: Management", section on 'Moderate hypertriglyceridemia'</a>.)</p><p></p><p class="bulletIndent1">Triglyceride levels between 500 and 800 mg/dL require additional intervention, such as reduction of the dose of <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a> and/or the addition of a lipid-lowering agent [<a href="#rid47">47</a>]. (See  <a class="medical medical_review" href="/z/d/html/4570.html" rel="external">"Hypertriglyceridemia in adults: Management", section on 'Treatment goals'</a>.) </p><p></p><p class="bulletIndent1">Severe hypertriglyceridemia (eg, above 800 mg/dL) may warrant cessation of <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a> therapy because of the risk of acute pancreatitis [<a href="#rid47">47,48</a>]. However, pancreatitis secondary to isotretinoin is rare [<a href="#rid49">49</a>].</p><p></p><p class="bulletIndent1">Although hypertriglyceridemia usually resolves with cessation of <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a>, patients may need ongoing monitoring since one report suggests that they may be at increased risk for future hyperlipidemia and metabolic syndrome [<a href="#rid28">28</a>]. In a cross-sectional study, 102 patients in whom the serum triglyceride concentration increased at least 89 mg/dL (1 mmol/L) during isotretinoin therapy (hyper-responders) were compared with 100 patients in whom the serum triglyceride concentration changed ≤9 mg/dL (0.1 mmol/L, nonresponders). Four years after completion of isotretinoin therapy, hyper-responders were significantly more likely to have hypertriglyceridemia (odds ratio [OR] 4.8, 95% CI 1.6-13.8), hypercholesterolemia (OR 9.1, 95% CI 1.9-43), truncal obesity (OR 11.0, 95% CI 2.0-59), and hyperinsulinemia (OR 3.0, 95% CI 1.6-5.7).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hepatic transaminase elevations</strong> – Mild, transient elevations in hepatic transaminases occur early in the course of therapy in approximately 15 to 20 percent of patients; levels typically normalize within a few weeks [<a href="#rid2">2</a>]. Discontinuation of <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a> is recommended if hepatic transaminase levels reach more than three times greater than normal values [<a href="#rid2">2,50</a>].</p><p></p><p class="headingAnchor" id="H3023270295"><span class="h3">Pregnancy</span><span class="headingEndMark"> — </span>Despite efforts to minimize risk for pregnancy during <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a> therapy, such as mandatory participation in the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fipledgeprogram.com%2F%23Main&amp;token=11npaxc5%2BtwYQNEbNxIvNQfcJaSKzBwVKphwr4ut8b7qoeyGYSAd9yUzO5kFibik&amp;TOPIC_ID=38" target="_blank">iPLEDGE program</a> in the United States, pregnancies still occur [<a href="#rid51">51</a>]. If pregnancy occurs during treatment, isotretinoin should be stopped immediately. The pregnant patient should be referred to an obstetrician-gynecologist with experience in reproductive toxicity for management and counseling [<a href="#rid52">52</a>]. In the United States, the iPLEDGE program requires reporting of pregnancies that occur during therapy.</p><p class="headingAnchor" id="H2428762165"><span class="h3">Other</span><span class="headingEndMark"> — </span>The management of other extracutaneous adverse effects of <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a> (eg, psychiatric effects, severe eye symptoms), may warrant consultation with appropriate specialists to determine the best course of action for individual patients. Patients with signs and symptoms suggestive of pseudotumor cerebri (eg, headache with new-onset vision changes) require specialist evaluation and should discontinue use of isotretinoin. (See  <a class="medical medical_review" href="/z/d/html/5257.html" rel="external">"Idiopathic intracranial hypertension (pseudotumor cerebri): Clinical features and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/5253.html" rel="external">"Idiopathic intracranial hypertension (pseudotumor cerebri): Prognosis and treatment"</a>.)</p><p class="headingAnchor" id="H3475702425"><span class="h1">STOPPING THERAPY</span><span class="headingEndMark"> — </span>In patients treated for severe acne, <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a> is usually discontinued after achievement of the goal cumulative dose of 120 to 150 mg/kg and acne clearance. The drug can be stopped abruptly; tapering is not necessary.</p><p class="headingAnchor" id="H553964564"><span class="h1">AFTER THERAPY</span></p><p class="headingAnchor" id="H2414812225"><span class="h2">Outcomes</span><span class="headingEndMark"> — </span>Oral <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a> is the only acne medication that can permanently alter the natural course of the disorder. The majority of patients experience long-term improvement in acne severity after one course of treatment [<a href="#rid53">53</a>]. In addition, continued improvement may occur for several months after cessation of therapy; thus, at least five months should elapse before considering retreatment with isotretinoin.</p><p>Response rates after a second course of <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a> are similar to those following the initial course of treatment [<a href="#rid50">50</a>].</p><p>Reported relapse rates for patients treated with 120 to 150 mg/kg of <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a> range between 20 and 60 percent [<a href="#rid40">40</a>]. In one study of 88 patients treated with isotretinoin for severe or refractory acne and followed for up to 10 years, 82 percent of patients who received cumulative doses less than 120 mg/kg relapsed (defined as deterioration in acne sufficient to merit systemic antibiotic or isotretinoin therapy) compared with only 20 percent of patients given greater than 120 mg/kg [<a href="#rid53">53</a>]. Most relapses (78 percent) occurred within the first 18 months after treatment. Patients with truncal acne relapsed more frequently than patients with predominantly facial acne (40 versus 20 percent).</p><p>In addition to cumulative dose less than 120 to 150 mg/kg in patients with severe acne and presence of truncal acne, additional risk factors for relapse include male sex, young age at time of <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a> initiation (&lt;16 years of age), postadolescent females with acne, females with polycystic ovary syndrome, and females not receiving antiandrogen therapy [<a href="#rid54">54,55</a>].</p><p>Patients who receive <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a> as young teenagers (under age 16) may also have an increased risk for relapse [<a href="#rid56">56</a>].</p><p class="headingAnchor" id="H4265080254"><span class="h2">Follow-up</span><span class="headingEndMark"> — </span>Individuals of childbearing potential require <strong>a final pregnancy test one month after completion of </strong><a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a>. We counsel patients to return for re-evaluation if acne recurs. Patients with scarring may benefit from referral to a clinician with expertise in the treatment of acne scars. (See  <a class="medical medical_review" href="/z/d/html/90260.html" rel="external">"Management of acne scars"</a>.) </p><p class="headingAnchor" id="H4065352350"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/114928.html" rel="external">"Society guideline links: Acne vulgaris"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/126613.html" rel="external">"Society guideline links: COVID-19 – Index of guideline topics"</a>.)</p><p class="headingAnchor" id="H13"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.) </p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/15326.html" rel="external">"Patient education: Acne (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/z/d/html/7634.html" rel="external">"Patient education: Acne (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H14"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mechanism of action</strong> – <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">Isotretinoin</a> is a treatment for acne vulgaris that is thought to improve acne through reducing sebum production, inhibiting the growth of <em>Cutibacterium</em> (formerly <em>Propionibacterium</em>) <em>acnes</em>, inhibiting comedogenesis, and altering the inflammatory response. (See <a class="local">'Mechanism of action'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> – <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">Isotretinoin</a> has multiple side effects, including teratogenicity, mucocutaneous disorders, myalgias, visual changes, idiopathic intracranial hypertension, hepatotoxicity, and hyperlipidemia. (See <a class="local">'Adverse effects'</a> above.)</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">Isotretinoin</a> is teratogenic and should<strong> not</strong> be administered in pregnancy. In the United States, all prescribing clinicians and patients are required to participate in the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fipledgeprogram.com%2F%23Main&amp;token=11npaxc5%2BtwYQNEbNxIvNQfcJaSKzBwVKphwr4ut8b7qoeyGYSAd9yUzO5kFibik&amp;TOPIC_ID=38" target="_blank">iPLEDGE program</a>, an online registry initiated by the US Food and Drug Administration (FDA) in an attempt to minimize the risk of fetal exposure to isotretinoin. (See <a class="local">'Teratogenicity'</a> above and <a class="local">'Patient counseling'</a> above and <a class="local">'iPLEDGE program'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dosing and administration</strong>:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>General approach</strong> – For the treatment of severe acne, <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a> is typically started at a low dose (0.5 mg/kg per day) during the first month of therapy and then increased to 1 mg/kg per day. A total dose of 120 to 150 mg/kg of isotretinoin is given over the course of treatment. The duration of treatment is often between 20 and 24 weeks or until acne is clear. (See <a class="local">'Dosing and administration'</a> above.)</p><p></p><p class="bulletIndent2">Other acne medications are typically discontinued during <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a> therapy. In particular, the use of isotretinoin with tetracyclines should be avoided due to the risk of idiopathic intracranial hypertension (pseudotumor cerebri). (See <a class="local">'Drug interactions'</a> above and <a class="local">'Use of other acne medications'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Acne conglobata and acne fulminans</strong> – Patients with severe inflammatory acne (eg, acne conglobata, acne fulminans) may require a lower initial dose and/or concomitant treatment with systemic glucocorticoids starting before or at the initiation of oral <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a> therapy. (See <a class="local">'Severe acne'</a> above and  <a class="medical medical_review" href="/z/d/html/129467.html" rel="external">"Acne vulgaris: Management of moderate to severe acne in adolescents and adults", section on 'Acne conglobata'</a> and  <a class="medical medical_review" href="/z/d/html/129467.html" rel="external">"Acne vulgaris: Management of moderate to severe acne in adolescents and adults", section on 'Acne fulminans'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Outcomes</strong> – Most patients improve after <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a> therapy, although the majority of patients will continue to require the use of other acne therapies. Continued improvement may occur for several months after isotretinoin therapy; therefore, subsequent courses of isotretinoin should not be initiated until at least five months after completion of the previous treatment period. (See <a class="local">'Outcomes'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Ward A, Brogden RN, Heel RC, et al. Isotretinoin. A review of its pharmacological properties and therapeutic efficacy in acne and other skin disorders. Drugs 1984; 28:6.</a></li><li><a class="nounderline abstract_t">Brelsford M, Beute TC. Preventing and managing the side effects of isotretinoin. Semin Cutan Med Surg 2008; 27:197.</a></li><li><a class="nounderline abstract_t">Dispenza MC, Wolpert EB, Gilliland KL, et al. Systemic isotretinoin therapy normalizes exaggerated TLR-2-mediated innate immune responses in acne patients. J Invest Dermatol 2012; 132:2198.</a></li><li><a class="nounderline abstract_t">Vallerand IA, Lewinson RT, Farris MS, et al. Efficacy and adverse events of oral isotretinoin for acne: a systematic review. Br J Dermatol 2018; 178:76.</a></li><li><a class="nounderline abstract_t">Neudorfer M, Goldshtein I, Shamai-Lubovitz O, et al. Ocular adverse effects of systemic treatment with isotretinoin. Arch Dermatol 2012; 148:803.</a></li><li><a class="nounderline abstract_t">Mathers WD, Shields WJ, Sachdev MS, et al. Meibomian gland morphology and tear osmolarity: changes with Accutane therapy. Cornea 1991; 10:286.</a></li><li><a class="nounderline abstract_t">Leyden JJ, James WD. Staphylococcus aureus infection as a complication of isotretinoin therapy. Arch Dermatol 1987; 123:606.</a></li><li><a class="nounderline abstract_t">Ellis CN, Krach KJ. Uses and complications of isotretinoin therapy. J Am Acad Dermatol 2001; 45:S150.</a></li><li><a class="nounderline abstract_t">López-Vílchez MA, Vicente Villa MA, García-Fructuoso MT, et al. [Acne fulminans after the treatment with isotretinoin]. An Esp Pediatr 1999; 51:200.</a></li><li><a class="nounderline abstract_t">Tan BB, Lear JT, Smith AG. Acne fulminans and erythema nodosum during isotretinoin therapy responding to dapsone. Clin Exp Dermatol 1997; 22:26.</a></li><li><a class="nounderline abstract_t">Lammer EJ, Chen DT, Hoar RM, et al. Retinoic acid embryopathy. N Engl J Med 1985; 313:837.</a></li><li><a class="nounderline abstract_t">Centers for Disease Control and Prevention (CDC). Accutane-exposed pregnancies--California, 1999. MMWR Morb Mortal Wkly Rep 2000; 49:28.</a></li><li><a class="nounderline abstract_t">Sladden MJ, Harman KE. What is the chance of a normal pregnancy in a woman whose fetus has been exposed to isotretinoin? Arch Dermatol 2007; 143:1187.</a></li><li><a class="nounderline abstract_t">Marqueling AL, Zane LT. Depression and suicidal behavior in acne patients treated with isotretinoin: a systematic review. Semin Cutan Med Surg 2005; 24:92.</a></li><li><a class="nounderline abstract_t">Magin P, Pond D, Smith W. Isotretinoin, depression and suicide: a review of the evidence. Br J Gen Pract 2005; 55:134.</a></li><li><a class="nounderline abstract_t">Hull PR, D'Arcy C. Acne, depression, and suicide. Dermatol Clin 2005; 23:665.</a></li><li><a class="nounderline abstract_t">Bigby M. Does isotretinoin increase the risk of depression? Arch Dermatol 2008; 144:1197.</a></li><li><a class="nounderline abstract_t">Huang YC, Cheng YC. Isotretinoin treatment for acne and risk of depression: A systematic review and meta-analysis. J Am Acad Dermatol 2017; 76:1068.</a></li><li><a class="nounderline abstract_t">Halvorsen JA, Stern RS, Dalgard F, et al. Suicidal ideation, mental health problems, and social impairment are increased in adolescents with acne: a population-based study. J Invest Dermatol 2011; 131:363.</a></li><li><a class="nounderline abstract_t">Vallerand IA, Lewinson RT, Parsons LM, et al. Risk of depression among patients with acne in the U.K.: a population-based cohort study. Br J Dermatol 2018; 178:e194.</a></li><li><a class="nounderline abstract_t">Sundström A, Alfredsson L, Sjölin-Forsberg G, et al. Association of suicide attempts with acne and treatment with isotretinoin: retrospective Swedish cohort study. BMJ 2010; 341:c5812.</a></li><li><a class="nounderline abstract_t">Kridin K, Ludwig RJ. Isotretinoin and the risk of psychiatric disturbances: A global study shedding new light on a debatable story. J Am Acad Dermatol 2023; 88:388.</a></li><li><a class="nounderline abstract_t">Etminan M, Bird ST, Delaney JA, et al. Isotretinoin and risk for inflammatory bowel disease: a nested case-control study and meta-analysis of published and unpublished data. JAMA Dermatol 2013; 149:216.</a></li><li><a class="nounderline abstract_t">Alhusayen RO, Juurlink DN, Mamdani MM, et al. Isotretinoin use and the risk of inflammatory bowel disease: a population-based cohort study. J Invest Dermatol 2013; 133:907.</a></li><li><a class="nounderline abstract_t">Kridin K, Ludwig RJ. Isotretinoin and the risk of inflammatory bowel disease and irritable bowel syndrome: A large-scale global study. J Am Acad Dermatol 2023; 88:824.</a></li><li><a class="nounderline abstract_t">Taylor MT, Margolis DJ, Kwatra SG, Barbieri JS. A propensity score matched cohort study identifying an association of acne, but not oral antibiotic or isotretinoin use, with risk of incident inflammatory bowel disease. J Am Acad Dermatol 2023; 88:841.</a></li><li><a class="nounderline abstract_t">Zane LT, Leyden WA, Marqueling AL, Manos MM. A population-based analysis of laboratory abnormalities during isotretinoin therapy for acne vulgaris. Arch Dermatol 2006; 142:1016.</a></li><li><a class="nounderline abstract_t">Rodondi N, Darioli R, Ramelet AA, et al. High risk for hyperlipidemia and the metabolic syndrome after an episode of hypertriglyceridemia during 13-cis retinoic acid therapy for acne: a pharmacogenetic study. Ann Intern Med 2002; 136:582.</a></li><li><a class="nounderline abstract_t">DiGiovanna JJ. Isotretinoin effects on bone. J Am Acad Dermatol 2001; 45:S176.</a></li><li><a class="nounderline abstract_t">Steele RG, Lugg P, Richardson M. Premature epiphyseal closure secondary to single-course vitamin A therapy. Aust N Z J Surg 1999; 69:825.</a></li><li><a class="nounderline abstract_t">Luthi F, Eggel Y, Theumann N. Premature epiphyseal closure in an adolescent treated by retinoids for acne: an unusual cause of anterior knee pain. Joint Bone Spine 2012; 79:314.</a></li><li><a class="nounderline abstract_t">Milstone LM, McGuire J, Ablow RC. Premature epiphyseal closure in a child receiving oral 13-cis-retinoic acid. J Am Acad Dermatol 1982; 7:663.</a></li><li><a class="nounderline abstract_t">Zaenglein AL, Pathy AL, Schlosser BJ, et al. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol 2016; 74:945.</a></li><li><a class="nounderline abstract_t">Spring LK, Krakowski AC, Alam M, et al. Isotretinoin and Timing of Procedural Interventions: A Systematic Review With Consensus Recommendations. JAMA Dermatol 2017; 153:802.</a></li><li><a class="nounderline abstract_t">Waldman A, Bolotin D, Arndt KA, et al. ASDS Guidelines Task Force: Consensus Recommendations Regarding the Safety of Lasers, Dermabrasion, Chemical Peels, Energy Devices, and Skin Surgery During and After Isotretinoin Use. Dermatol Surg 2017; 43:1249.</a></li><li><a class="nounderline abstract_t">Kovitwanichkanont T, Driscoll T. A comparative review of the isotretinoin pregnancy risk management programs across four continents. Int J Dermatol 2018; 57:1035.</a></li><li class="breakAll">iPLEDGE Risk Evaluation and Mitigation Strategy. www.ipledgeprogram.com (Accessed on April 23, 2009).</li><li><a class="nounderline abstract_t">Xia E, Han J, Faletsky A, et al. Isotretinoin Laboratory Monitoring in Acne Treatment: A Delphi Consensus Study. JAMA Dermatol 2022; 158:942.</a></li><li><a class="nounderline abstract_t">Webster GF, Leyden JJ, Gross JA. Comparative pharmacokinetic profiles of a novel isotretinoin formulation (isotretinoin-Lidose) and the innovator isotretinoin formulation: a randomized, 4-treatment, crossover study. J Am Acad Dermatol 2013; 69:762.</a></li><li><a class="nounderline abstract_t">Blasiak RC, Stamey CR, Burkhart CN, et al. High-dose isotretinoin treatment and the rate of retrial, relapse, and adverse effects in patients with acne vulgaris. JAMA Dermatol 2013; 149:1392.</a></li><li><a class="nounderline abstract_t">Cyrulnik AA, Viola KV, Gewirtzman AJ, Cohen SR. High-dose isotretinoin in acne vulgaris: improved treatment outcomes and quality of life. Int J Dermatol 2012; 51:1123.</a></li><li><a class="nounderline abstract_t">Costa CS, Bagatin E, Martimbianco ALC, et al. Oral isotretinoin for acne. Cochrane Database Syst Rev 2018; 11:CD009435.</a></li><li><a class="nounderline abstract_t">Lee JW, Yoo KH, Park KY, et al. Effectiveness of conventional, low-dose and intermittent oral isotretinoin in the treatment of acne: a randomized, controlled comparative study. Br J Dermatol 2011; 164:1369.</a></li><li><a class="nounderline abstract_t">Hansen TJ, Lucking S, Miller JJ, et al. Standardized laboratory monitoring with use of isotretinoin in acne. J Am Acad Dermatol 2016; 75:323.</a></li><li><a class="nounderline abstract_t">Lee YH, Scharnitz TP, Muscat J, et al. Laboratory Monitoring During Isotretinoin Therapy for Acne: A Systematic Review and Meta-analysis. JAMA Dermatol 2016; 152:35.</a></li><li><a class="nounderline abstract_t">Shah R, Kroshinsky D. Re-evaluating the need for routine laboratory monitoring in patients taking isotretinoin: A retrospective analysis. J Am Acad Dermatol 2021; 85:504.</a></li><li class="breakAll">Patton TJ, Ferris LK. Systemic retinoids. In: Comprehensive Dermatologic Drug Therapy, 3rd ed, Wolverton SE (Ed), Elsevier, 2013. p.262.</li><li><a class="nounderline abstract_t">McCarter TL, Chen YK. Marked hyperlipidemia and pancreatitis associated with isotretinoin therapy. Am J Gastroenterol 1992; 87:1855.</a></li><li><a class="nounderline abstract_t">Opel D, Kramer ON, Chevalier M, et al. Not every patient needs a triglyceride check, but all can get pancreatitis: a systematic review and clinical characterization of isotretinoin-associated pancreatitis. Br J Dermatol 2017; 177:960.</a></li><li class="breakAll">Patton TJ, Zirwas MJ, Wolverton SE. Systemic retinoids. In: Comprehensive Dermatologic Drug Therapy, 2nd ed, Wolverton SE (Ed), Elsevier, 2007. p.275.</li><li><a class="nounderline abstract_t">Tkachenko E, Singer S, Sharma P, et al. US Food and Drug Administration Reports of Pregnancy and Pregnancy-Related Adverse Events Associated With Isotretinoin. JAMA Dermatol 2019; 155:1175.</a></li><li class="breakAll">https://www.ipledgeprogram.com/iPledgeUI/rems/pdf/resources/Prescriber%20Isotretinoin%20Educational%20Kit.pdf (Accessed on January 18, 2019).</li><li><a class="nounderline abstract_t">Layton AM, Knaggs H, Taylor J, Cunliffe WJ. Isotretinoin for acne vulgaris--10 years later: a safe and successful treatment. Br J Dermatol 1993; 129:292.</a></li><li><a class="nounderline abstract_t">Morales-Cardona CA, Sánchez-Vanegas G. Acne relapse rate and predictors of relapse following treatment with oral isotretinoin. Actas Dermosifiliogr 2013; 104:61.</a></li><li><a class="nounderline abstract_t">Goulden V, Clark SM, Cunliffe WJ. Post-adolescent acne: a review of clinical features. Br J Dermatol 1997; 136:66.</a></li><li><a class="nounderline abstract_t">Azoulay L, Oraichi D, Bérard A. Isotretinoin therapy and the incidence of acne relapse: a nested case-control study. Br J Dermatol 2007; 157:1240.</a></li></ol></div><div id="topicVersionRevision">Topic 38 Version 36.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6235105" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Isotretinoin. A review of its pharmacological properties and therapeutic efficacy in acne and other skin disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18786498" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Preventing and managing the side effects of isotretinoin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22513780" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Systemic isotretinoin therapy normalizes exaggerated TLR-2-mediated innate immune responses in acne patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28542914" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Efficacy and adverse events of oral isotretinoin for acne: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22508771" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Ocular adverse effects of systemic treatment with isotretinoin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1832371" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Meibomian gland morphology and tear osmolarity: changes with Accutane therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3472492" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Staphylococcus aureus infection as a complication of isotretinoin therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11606947" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Uses and complications of isotretinoin therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10495512" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : [Acne fulminans after the treatment with isotretinoin].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9330049" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Acne fulminans and erythema nodosum during isotretinoin therapy responding to dapsone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3162101" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Retinoic acid embryopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10680601" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Accutane-exposed pregnancies--California, 1999.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17875883" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : What is the chance of a normal pregnancy in a woman whose fetus has been exposed to isotretinoin?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16092797" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Depression and suicidal behavior in acne patients treated with isotretinoin: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15720936" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Isotretinoin, depression and suicide: a review of the evidence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16112443" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Acne, depression, and suicide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18794466" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Does isotretinoin increase the risk of depression?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28291553" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Isotretinoin treatment for acne and risk of depression: A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20844551" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Suicidal ideation, mental health problems, and social impairment are increased in adolescents with acne: a population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29411352" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Risk of depression among patients with acne in the U.K.: a population-based cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21071484" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Association of suicide attempts with acne and treatment with isotretinoin: retrospective Swedish cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36273659" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Isotretinoin and the risk of psychiatric disturbances: A global study shedding new light on a debatable story.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23426479" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Isotretinoin and risk for inflammatory bowel disease: a nested case-control study and meta-analysis of published and unpublished data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23096714" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Isotretinoin use and the risk of inflammatory bowel disease: a population-based cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36529376" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Isotretinoin and the risk of inflammatory bowel disease and irritable bowel syndrome: A large-scale global study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36682724" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : A propensity score matched cohort study identifying an association of acne, but not oral antibiotic or isotretinoin use, with risk of incident inflammatory bowel disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16924051" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : A population-based analysis of laboratory abnormalities during isotretinoin therapy for acne vulgaris.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11955026" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : High risk for hyperlipidemia and the metabolic syndrome after an episode of hypertriglyceridemia during 13-cis retinoic acid therapy for acne: a pharmacogenetic study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11606950" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Isotretinoin effects on bone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10553976" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Premature epiphyseal closure secondary to single-course vitamin A therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22154700" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Premature epiphyseal closure in an adolescent treated by retinoids for acne: an unusual cause of anterior knee pain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6958690" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Premature epiphyseal closure in a child receiving oral 13-cis-retinoic acid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26897386" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Guidelines of care for the management of acne vulgaris.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28658462" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Isotretinoin and Timing of Procedural Interventions: A Systematic Review With Consensus Recommendations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28498204" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : ASDS Guidelines Task Force: Consensus Recommendations Regarding the Safety of Lasers, Dermabrasion, Chemical Peels, Energy Devices, and Skin Surgery During and After Isotretinoin Use.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29508918" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : A comparative review of the isotretinoin pregnancy risk management programs across four continents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29508918" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : A comparative review of the isotretinoin pregnancy risk management programs across four continents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35704293" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Isotretinoin Laboratory Monitoring in Acne Treatment: A Delphi Consensus Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23953888" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Comparative pharmacokinetic profiles of a novel isotretinoin formulation (isotretinoin-Lidose) and the innovator isotretinoin formulation: a randomized, 4-treatment, crossover study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24173086" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : High-dose isotretinoin treatment and the rate of retrial, relapse, and adverse effects in patients with acne vulgaris.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22909370" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : High-dose isotretinoin in acne vulgaris: improved treatment outcomes and quality of life.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30484286" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Oral isotretinoin for acne.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21114478" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Effectiveness of conventional, low-dose and intermittent oral isotretinoin in the treatment of acne: a randomized, controlled comparative study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27189824" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Standardized laboratory monitoring with use of isotretinoin in acne.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26630323" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Laboratory Monitoring During Isotretinoin Therapy for Acne: A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30315820" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Re-evaluating the need for routine laboratory monitoring in patients taking isotretinoin: A retrospective analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30315820" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Re-evaluating the need for routine laboratory monitoring in patients taking isotretinoin: A retrospective analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1449157" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Marked hyperlipidemia and pancreatitis associated with isotretinoin therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27893168" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Not every patient needs a triglyceride check, but all can get pancreatitis: a systematic review and clinical characterization of isotretinoin-associated pancreatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27893168" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Not every patient needs a triglyceride check, but all can get pancreatitis: a systematic review and clinical characterization of isotretinoin-associated pancreatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31314041" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : US Food and Drug Administration Reports of Pregnancy and Pregnancy-Related Adverse Events Associated With Isotretinoin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31314041" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : US Food and Drug Administration Reports of Pregnancy and Pregnancy-Related Adverse Events Associated With Isotretinoin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8286227" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Isotretinoin for acne vulgaris--10 years later: a safe and successful treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22795452" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Acne relapse rate and predictors of relapse following treatment with oral isotretinoin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9039297" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Post-adolescent acne: a review of clinical features.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17970803" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Isotretinoin therapy and the incidence of acne relapse: a nested case-control study.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
